Clinical Use of DermaBind TL/FM: Advancing Hard-to-Heal Wound Care
Summary: This retrospective case series details real-world clinical experiences with DermaBind TL and FM, dehydrated intact placental membrane allografts from HealthTech Wound Care, applied to hard-to-heal chronic wounds after 30 days of standard therapy failure. Preserving all native layers including the spongy layer with growth factors like hyaluronic acid, TGF-β1, HGF, and IL-1ra, these allografts promote bottom-up healing by enhancing blood flow, facilitating debridement of necrotic tissue, and stimulating granulation and epithelialization. Results indicate faster closure (4-6 weeks vs. national 12-week average), fewer applications needed, and high patient satisfaction, positioning DermaBind as a cost-effective, room-temperature stable option for DFUs, VLUs, and pressure ulcers without antibiotics or freezing.
Key Highlights:
- DermaBind’s proprietary preservation retains comprehensive collagen matrix, glycoconjugates, and cytokines for superior regenerative support in stalled wounds.
- Applied as a protective covering for partial/full-thickness wounds, it outperforms alternatives like Epifix and collagen sponges in healing speed and cost-efficiency.
- Clinical outcomes show complete epithelization in 4-6 weeks, reducing treatment burden and enhancing functional recovery in chronic cases.
- Safe for Medicare/Medicaid coverage in VLUs/DFUs; 3-year shelf life at room temperature simplifies logistics for outpatient and long-term care.
- Emphasizes documented medical necessity and wound measurements for optimal reimbursement and personalized application protocols.
Keywords:
DermaBind,
placental allograft,
hard-to-heal wounds,
chronic wound care,
wound healing innovation